Professional traders are buying biotechnology shares during the market's decline because the sector has decoupled from the broader selloff and is riding a wave of takeovers. Biotechnology—companies that develop drugs and therapies from living systems—held roughly flat early in 2026 even as major indices swung, giving traders a place to hide while still owning growth. The deeper reason is timing. A looming wave of expiring drug patents is forcing large pharmaceutical firms to buy smaller biotech companies, and those buyouts reward shareholders who bought in before the deals.
Table of Contents
- The short answer: stability plus takeover premiums
- What is driving the buying—the patent cliff
- The deal wave making it real
- The risks a buyer should weigh
- How a retail investor can approach it
- Frequently Asked Questions
The short answer: stability plus takeover premiums
Two forces explain the buying. First, biotech behaved defensively: the iShares Biotechnology etf (IBB) was roughly flat early in 2026 while broad indices dropped, according to Seeking Alpha's review of the sector. Traders like assets that hold value when everything else falls.
Second, the sector had already outperformed over the prior year. As of early April 2026, the SPDR S&P Biotech ETF (XBI) was up 40.8% and IBB up 33.95% over the trailing year, 24/7 Wall St. reported using state Street and iShares data. Strength during weakness attracts momentum capital.
What is driving the buying—the patent cliff
The core catalyst is a "patent cliff." When a drug's patent expires, cheaper generics or biosimilars can enter, and the original maker loses much of that revenue. An estimated $200 billion to $400 billion of branded pharmaceutical revenue faces loss of exclusivity between 2025 and 2030, DrugPatentWatch estimates. The 2026 expirations are concrete.
They include Merck's Januvia (about $2.26 billion), Pfizer's Xeljanz (about $1.62 billion), and Merck's Janumet (about $1.43 billion), per GEN's patent-cliff tracker; Keytruda's core patent expires in 2028. To refill pipelines, large drugmakers buy smaller biotechs that own promising experimental treatments. That demand is what traders are positioning ahead of.
The deal wave making it real
Takeovers are running at record strength. Pharma and life-sciences deal value topped $65 billion in the first quarter of 2026—the strongest quarter since 2020, with 16 deals worth $1 billion or more—according to the PwC Pharma & Life Sciences deals outlook. Full-year flow reached roughly $106 billion across 201 transactions, PitchBook data cited by Seeking Alpha shows.
Deals like Biogen's roughly $5.6 billion purchase of Apellis carried buyout premiums that lifted the sector, since acquirers typically pay well above the market price. Cheap valuations feed the cycle. Median biotech enterprise-value-to-sales sat near 4x in the first quarter of 2026, versus 6–8x in early 2020, IntuitionLabs reports—making both accumulation and acquisition attractive.
The risks a buyer should weigh
Momentum is not one-directional. XBI's MACD histogram—a trend-following indicator—turned negative on June 2, 2026, a bearish technical signal that the rally can reverse, per Tickeron's XBI data. Technical strength earlier in the year does not guarantee it continues.
Deal flow may also broaden only slowly. Analysts expect M&A to improve "selectively," with valuation gaps, cautious buyers, and an unpredictable U.S. FDA climate—including surprise rejections and delays—still capping upside, according to a BioPharma Dive outlook. A single regulatory decision can sink an individual stock overnight.
How a retail investor can approach it
The professional case rests on the sector, not on guessing which small company gets bought. A few practical steps:.
- Prefer a broad biotech ETF (such as XBI or IBB) over a single stock, so one FDA rejection does not wipe out your position.
- Treat takeover premiums as a bonus, not a plan—do not buy a company only because you hope it is acquired.
- Check valuation context: the current appeal partly rests on multiples being below their 2020 levels.
- Size the position for volatility, since technical signals have already flashed bearish.
- Use the PwC 2026 M&A midyear outlook to track whether deal momentum holds.
Frequently Asked Questions
Does a patent cliff hurt or help biotech stocks?
It can help smaller biotechs. Big drugmakers losing patent-protected revenue often buy them at a premium to refill pipelines, rewarding existing shareholders.
Is an ETF safer than a single biotech stock here?
Generally yes for diversification. A broad fund spreads out the risk that one company faces an FDA rejection, though the whole sector can still fall together.
What would signal the trade is turning?
Watch technical reversals and deal flow. XBI's MACD already turned negative in June 2026, and a slowdown in billion-dollar acquisitions would weaken the core thesis.